AN2 Therapeutics, Inc. (ANTX)

CIK 0001880438 · Healthcare · Biotechnology

Recent Filing Index

Form Filed Qtr End F_Period 8K: Earnings Release
Latest Q1-2026 8-K (2026-05-11) · 99.1
Latest FY-2025 8-K (2026-03-17) · 99.1
Q3-2025 8-K (2025-11-12) · 99.1
Q2-2025 —
Q1-2025 —
FY-2024 8-K (2025-03-25) · 99.1
Q3-2024 8-K (2024-11-13) · 99.1
Q2-2024 8-K (2024-08-13) · 99.1
Q1-2024 8-K (2024-05-14) · 99.1
FY-2023
FY-2023 8-K (2024-03-28) · 99.1
Q3-2023 8-K (2023-11-09) · 99.1
Q2-2023 8-K (2023-08-10) · 99.1

Filing Summary

Report Name | Notes Fiscal Period (Annual) Fiscal Period (Quarter)
Document and Entity Information
Statements
Balance Sheets
Balance Sheets (P)
Statements of Operations and Comprehensive Loss
Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (deficit)
Statements of Stockholders' Equity
Condensed Statements of Stockholders' Equity (P)
—
Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (deficit) (P)
Statements of Stockholders' Equity (deficit) (P)
—
Statements of Cash Flows
Notes
Balance Sheet Components
Basis of Presentation and Summary of Significant Accounting Policies
—
Collaboration and License Agreements
Collaboration, License and Other Agreements
—
Commitments and Contingencies
Cybersecurity Risk Management, Strategy, and Governance
—
Equity
Equity Incentive Plan and Stock-based Compensation
Fair Value Measurements
Funding Arrangements
Income Taxes
—
Insider Trading Arrangements
Insider Trading Policies and Procedures
—
Leases
—
Net Loss Per Share
Organization and Description of Business
Pay Vs Performance Disclosure
Related Party Transactions
Restructuring Charges
Segment Reporting
Subsequent Events
Summary of Significant Accounting Policies
—